Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions

Schizophrenia, which affects around 1% of the world’s population, has been described as a complex set of symptoms triggered by multiple factors. However, the exact background mechanisms remain to be explored, whereas therapeutic agents with excellent effectivity and safety profiles have yet to be de...

Descripción completa

Detalles Bibliográficos
Autores principales: Zádor, Ferenc, Nagy-Grócz, Gábor, Kekesi, Gabriella, Dvorácskó, Szabolcs, Szűcs, Edina, Tömböly, Csaba, Horvath, Gyongyi, Benyhe, Sándor, Vécsei, László
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832375/
https://www.ncbi.nlm.nih.gov/pubmed/31619006
http://dx.doi.org/10.3390/molecules24203709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832375/
https://www.ncbi.nlm.nih.gov/pubmed/31619006
http://dx.doi.org/10.3390/molecules24203709

Ejemplares similares